Skip to main navigation
Avadel Pharmaceuticals
  • Recent News
  • Investors
  • About
    • Overview
    • Leadership
    • Board of Directors
    • Business Development
    • Corporate Responsibility
  • Research
    • Clinical Trials
  • Contact Us
  • Call Today
  • Email Us
  • Our Map
    • Avadel Pharmaceuticals
    • 636.449.1830
    • Home
    • About
      • Overview
      • Leadership
      • Board of Directors
      • Business Development
      • Corporate Responsibility
    • Research Pipeline
      • Clinical Trials
    • Investor Relations

      • Investors
      • News & Events
        • Press Releases
        • Events
        • Presentations
      • Stock Information
        • Stock Quote & Chart
        • Historical Price Lookup
        • Investment Calculator
        • Analyst Coverage
      • Financial Information
        • SEC Filings
        • Financial Reports
        • Quarterly Results
      • Corporate Governance
        • Governance Highlights
        • Management Team
        • Board of Directors
        • Committee Composition
        • Annual General Meeting
      • Shareholder Services
        • Investor FAQs
        • Information Request
        • E-mail Alerts
        • IR Contacts
    • Contact Us
646.449.1830

Breadcrumb

  1. Home
  2. Investors
  3. Press Releases

Press Releases

Keyword Search

12/16/20

Avadel Pharmaceuticals Announces Submission of New Drug Application for FT218 to the FDA
DUBLIN, Ireland , Dec. 16, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL) today ...
Printer Friendly Version
12/15/20

Avadel Pharmaceuticals Added to NASDAQ Biotechnology Index
DUBLIN, Ireland , Dec. 15, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a com...
Printer Friendly Version
12/07/20

Avadel Pharmaceuticals Appoints Dr. Jennifer Gudeman as Vice President of Medical and Clinical Affairs
DUBLIN, Ireland , Dec. 07, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a com...
Printer Friendly Version
11/23/20

Avadel Pharmaceuticals to Present at Upcoming December 2020 Investor Conferences
DUBLIN, Ireland , Nov. 23, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a com...
Printer Friendly Version
11/11/20

Avadel Pharmaceuticals to Present at Upcoming November 2020 Investor Conferences
DUBLIN, Ireland , Nov. 11, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a com...
Printer Friendly Version
11/09/20

Avadel Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Update on FT218 Development Program
NDA   for once-nightly FT218 is on track for FDA submission by end of December 2020 New market asses...
Printer Friendly Version
10/26/20

Avadel Pharmaceuticals to Report Third Quarter 2020 Financial Results on November 9th
DUBLIN, Ireland , Oct. 26, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a com...
Printer Friendly Version
09/17/20

Avadel to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
DUBLIN, Ireland , Sept. 17, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL) a com...
Printer Friendly Version
09/14/20

Avadel Pharmaceuticals Announces FT218 Leadership Transition
Jordan Dubow , M.D. stepping down as CMO and will continue as a consultant to the Company through th...
Printer Friendly Version
09/11/20

Avadel to Present at H.C. Wainwright 22nd Annual Global Investment Conference
DUBLIN, Ireland , Sept. 11, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL) a com...
Printer Friendly Version
08/10/20

Avadel Pharmaceuticals Reports Second Quarter 2020 Financial Results and Recent Business Update
Presented positive topline data from the pivotal Phase 3 REST-ON study Announced today that results ...
Printer Friendly Version
07/27/20

Avadel Pharmaceuticals to Report Second Quarter 2020 Financial Results on August 10th
DUBLIN, Ireland , July 27, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL) announ...
Printer Friendly Version
07/13/20

Avadel Pharmaceuticals Announces First Patient Dosed in Open-Label Extension/Switch Study of Investigational Once-Nightly FT218 as a Potential Treatment for Excessive Daytime Sleepiness and Cataplexy in Patients with Narcolepsy
Clinical study to enroll 250 patients from sites that participated in the REST-ON study Study to exa...
Printer Friendly Version
07/01/20

Avadel Announces Sale of Hospital Sterile Injectable Drug Portfolio for $42.0 Million
DUBLIN, Ireland , July 01, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a com...
Printer Friendly Version
06/08/20

Avadel Pharmaceuticals to Present at BIO Digital
DUBLIN, Ireland , June 08, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL) a comp...
Printer Friendly Version
06/01/20

Avadel Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference
DUBLIN, Ireland , June 01, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL) a comp...
Printer Friendly Version
05/11/20

Avadel Pharmaceuticals Reports First Quarter 2020 Financial Results
Reported positive topline data from the pivotal Phase 3 REST-ON study Strengthened balance sheet wit...
Printer Friendly Version
05/04/20

Avadel Pharmaceuticals to Report First Quarter 2020 Financial Results on May 11th
DUBLIN, Ireland , May 04, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a comp...
Printer Friendly Version
04/28/20

Avadel Pharmaceuticals Announces Pricing of Public Offering
DUBLIN, Ireland , April 28, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a co...
Printer Friendly Version
04/27/20

Avadel Pharmaceuticals Announces Proposed Underwritten Public Offering
DUBLIN, Ireland , April 27, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a co...
Printer Friendly Version
04/27/20

Avadel Pharmaceuticals Announces Positive Topline Results from its Pivotal Phase 3 REST-ON Trial of Once-Nightly FT218 for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Patients with Narcolepsy
The primary analysis of investigational, once-nightly FT218 at 9 g demonstrated highly statistically...
Printer Friendly Version
03/25/20

Avadel Pharmaceuticals Completes the REST-ON Phase 3 Pivotal Trial of FT218 for Excessive Daytime Sleepiness and Cataplexy in Patients with Narcolepsy
Topline data from the REST-ON study expected in Q2 2020 DUBLIN, Ireland , March 25, 2020 (GLOBE NEWS...
Printer Friendly Version
03/12/20

Avadel Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results
Completed enrollment for the pivotal REST-ON Phase 3 study in Q4 2019; data readout expected in Q2 2...
Printer Friendly Version
02/27/20

Avadel Pharmaceuticals to Report Fourth Quarter and Year End 2019 Financial Results on March 12th
DUBLIN, Ireland , Feb. 27, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a com...
Printer Friendly Version
02/21/20

Avadel Pharmaceuticals Announces $65 Million Private Placement with Leading Biotech Investment Funds
DUBLIN, Ireland , Feb. 21, 2020 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a com...
Printer Friendly Version

Tools

  • Print Page
  • RSS
  • E-mail Alerts

Investor Relations

  • Investors
  • News & Events
    • Press Releases
    • Events
    • Presentations
  • Stock Information
    • Stock Quote & Chart
    • Historical Price Lookup
    • Investment Calculator
    • Analyst Coverage
  • Financial Information
    • SEC Filings
    • Financial Reports
    • Quarterly Results
  • Corporate Governance
    • Governance Highlights
    • Management Team
    • Board of Directors
    • Committee Composition
    • Annual General Meeting
  • Shareholder Services
    • Investor FAQs
    • Information Request
    • E-mail Alerts
    • IR Contacts

Contact Avadel Pharmaceuticals Today

Avadel Pharmaceuticals

Helpful Links Site Map | Privacy Policy | Terms and Conditions

  • Overview
  • News & Events
  • Careers
  • Investors
  • Contact Us
16640 Chesterfield Grove Road,
Suite 200,
Saint Louis, MO 63005 |  View Map [+]
http://www.avadel.com/
Site Map | Privacy Policy
http://www.avadel.com/

© COPYRIGHT AVADEL PHARMACEUTICALS, PLC. ALL RIGHTS RESERVED

0117 AVL WBST MAIN_KP2